MT
Mati Therapeutics Inc.
SEC filingBiotechnology · Austin, TX
Amount raised$2.6Msold at filing
Total offering$4.9M$2.2M still open
Investors in the raise2count reported to the SEC
FiledJul 2, 2026first sale Sep 12, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Linda LupiniDirector
Jim MazzoDirector
Ken JonesDirector
Dave FellowsDirector
Cameron NelsonExecutive Officer
Peter McDonnellDirector
Christopher MullerExecutive Officer, Director
Robert ButchofskyExecutive Officer, Director
Joseph Tortorice IIIDirector
Executive officers, directors and promoters as listed on the Form D.